Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i>-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.Aaron Lisberg, Steven M. Dubinett, Camelia Dumitras et al.|Journal of Clinical Oncology|2021Cited by 2